MedTrace Logo

Percutaneous Edge To Edge Repair for the Treatment of Severe Tricuspid Valve Regurgitation in High-surgical Risk Patients With Systemic Right Ventricle : a Multicentric French Cohort (PETER-TRESRIV)

NCT05052177 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 10

Last updated 2021-09-22

No results posted yet for this study

Summary

Our study is about to follow adult congenital patients, known with systemic right ventricle (mostly correct transposition of the great arteries ou congenitally corrected transposition fo the great arteries) and systemic valve severe regurgitation which was treated with a Mitraclip device on this tricuspid valve.

It's an observationnal study with a 2 years follow up with clinical (symptoms, complications, VO2 exercice test) echographic and MRI outcomes

.

Conditions

  • Systemic Right Ventricle
  • Tricuspid Regurgitation
  • Congenital Heart Disease

Interventions

DEVICE

Edge to edge repair in systemic tricuspid valve regurgitation

Edge to edge repair of severe tricuspid regurgitation on a right systemic ventricle with a Mitraclip device.

Sponsors & Collaborators

  • University of Bordeaux

    lead OTHER

Principal Investigators

  • Alexandre SILINI · University Hospital, Bordeaux

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-07-01
Primary Completion
2022-10-30
Completion
2022-10-30
FDA Device
Yes

Countries

  • France

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05052177 on ClinicalTrials.gov